{
    "pmcid": "9990171",
    "summary": "The paper titled \"Avidity engineering of human heavy-chain-only antibodies mitigates neutralization resistance of SARS-CoV-2 variants\" explores innovative strategies to design antibodies that can effectively neutralize SARS-CoV-2, including its variants of concern (VOCs) such as Omicron. The study focuses on the spike protein of SARS-CoV-2, which is the primary target for neutralizing antibodies due to its role in virus-cell entry.\n\n### Key Insights on SARS-CoV-2 Spike Protein:\n\n1. **Structure and Function**:\n   - The spike (S) protein is a class I fusion protein that facilitates the entry of the virus into host cells. It forms a homotrimer and is divided into two subunits: S1 and S2.\n   - The S1 subunit contains the N-terminal domain (NTD) and the receptor-binding domain (RBD), which are critical for virus attachment and entry. The RBD binds to the human ACE2 receptor, and its conformation (open or closed) affects its ability to engage ACE2.\n\n2. **Antibody Targeting**:\n   - Neutralizing antibodies primarily target the NTD and RBD of the spike protein. The RBD has four major antibody classes, with class 1 and 2 epitopes overlapping the ACE2-binding site.\n   - The NTD is targeted by antibodies that recognize a single antigenic supersite composed of multiple loops.\n\n3. **Challenges with Variants**:\n   - SARS-CoV-2 variants, such as Beta, Gamma, and Omicron, have mutations in the spike protein that reduce the efficacy of many existing antibodies by altering the epitopes in the NTD and RBD.\n   - These mutations lead to decreased binding affinity and neutralization potency, necessitating new strategies for antibody design.\n\n### Designing SARS-CoV-2 Nanobody Binders:\n\n1. **Multispecific and Multivalent Antibodies**:\n   - The study introduces a biparatopic heavy-chain-only antibody with six antigen-binding sites targeting two distinct epitopes in the spike protein's NTD and RBD.\n   - This hexavalent antibody format enhances neutralization potency and breadth against SARS-CoV-2 variants, including Omicron sub-lineages.\n\n2. **Avidity Engineering**:\n   - Avidity refers to the cumulative binding strength of multiple antigen-binding sites. By increasing valency, the apparent affinity for the target antigen is enhanced.\n   - The hexavalent antibody design mitigates the decrease in spike trimer affinity caused by escape mutations, thereby maintaining neutralization efficacy.\n\n3. **Single-Domain Antibodies (sdAbs)**:\n   - sdAbs, derived from camelids and sharks, are advantageous for engineering due to their single-chain format, which simplifies the creation of multimeric and multispecific antibodies.\n   - The study utilizes human heavy-chain-only antibodies (HCAbs) from transgenic mice, linking multiple VH domains to create tetravalent and hexavalent antibodies.\n\n4. **Broad Neutralization Capacity**:\n   - The hexavalent antibody demonstrated broad neutralization against various SARS-CoV-2 VOCs, including Omicron subvariants, which the parental antibodies could not neutralize effectively.\n   - This design provides a framework for developing therapeutic antibodies capable of overcoming neutralization escape by emerging variants.\n\n5. **Therapeutic Potential**:\n   - The inclusion of the Fc region in the antibody design confers additional benefits, such as prolonged serum half-life and potential recruitment of Fc-mediated effector functions.\n   - The fully human nature of the multimerized antibodies reduces the risk of immunogenicity and antidrug antibody formation, making them suitable for therapeutic applications.\n\nIn summary, the paper highlights the potential of avidity engineering and multimerization of single-domain antibodies to create potent and broad-spectrum therapeutics against SARS-CoV-2 and its variants. By targeting multiple epitopes on the spike protein and increasing antibody valency, the study provides a promising approach to counteract the challenges posed by antigenically drifted variants.",
    "title": "Avidity engineering of human heavy-chain-only antibodies mitigates neutralization resistance of SARS-CoV-2 variants"
}